Duloxetine Capsule, Delayed Release
Product Images NDC 80425-0311

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 80425-0311). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Advanced Rx Pharmacy Of Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label 1 (Duloxetine Dr 20mg 80425 0311 01)

This is a medication package of Duloxetine 20mg Capsule DR with 30 capsules. It contains an NDC code of 80425-0311-01 and the lot number is 000000000. The package expires on 10/31/2024 and also includes a serial number of 000000138240. The rest of the text does not provide any useful information.*

FDA Label Image

Label 2 (Duloxetine Dr 20mg 80425 0311 02)

This is a description of a medication called Duloxetine 20mg capsule DR. The packaging contains 60 capsules and has been assigned a lot number (X000000K) with an expiry date of 10/31/2024. The medication was packed by a company called Boemarasc TR and has been assigned a serial number of 000000138244.*

FDA Label Image

Label 3 (Duloxetine Dr 20mg 80425 0311 03)

This is a description of a medication package containing Duloxetine 20mg capsules, a generic alternative to the brand name Cymbalta. The package contains 90 capsules and the lot number is 0000001 38248. The expiration date is October 31st, 2023. The remaining text is not available or not readable.*

FDA Label Image

Figure 10 (Image 11)

FDA Label Image

Figure 1 (Image 2)

This is a graph showing the number of patients experiencing relapse over time from randomization to relapse in days while being treated with either placebo or Duloxetine. The x-axis shows the time from randomization to relapse in days, and the y-axis shows the number of patients. The graph includes two lines, one for the placebo and the other for Duloxetine.*

FDA Label Image

Figure 3 (Image 4)

FDA Label Image

Figure 4 (Image 6)

FDA Label Image

Structure (Image 7)

This appears to be a chart showing the percentage of patients who improved with different treatments of duloxetine at various doses. The chart compares 60mg of duloxetine taken twice daily versus 60mg taken once daily, as well as a placebo. It also displays the percent improvement in pain from the baseline.*

FDA Label Image

Figure 6 (Image 8)

FDA Label Image

Figure 8 (Image 9)

This is a description of a clinical trial that involves the use of Duloxetine, a medication used for the treatment of depression and anxiety disorders. The medication is administered at a dosage of either 60 or 120 mg once daily. The text includes a chart indicating the percent improvement in pain from baseline. The word "Placebo" at the beginning suggests that the trial might involve a placebo control group.*

FDA Label Image

Structure (Image)

FDA Label Image

Figure 9 (Image10)

FDA Label Image

Structure (Image3)

This is a chart showing the proportion of patients with relapse over time from randomization to relapse (in days) for patients with placebo and duloxetine treatment.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.